Top Markets
Coin of the day
Septerna Inc Septerna Inc

Septerna Inc

SEPN
Rang in Aktien #6851
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops... Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Aktienkurs
$40.61
Zuletzt synchronisiert: 2026-08-27
Marktkapitalisierung
$1.83B
Veränderung (1 Tag)
0.89%
Veränderung (1 Jahr)
230.70%
Land
US
Handel Septerna Inc (SEPN)

Kategorie

Kursverlauf für Septerna Inc (SEPN)
Höchster Schlusskurs: $42.39 am 2026-08-01

Niedrigster Schlusskurs: $21.08 am 2024-10-01
Kursverlauf der Aktie von Septerna Inc von 2024 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) -1.18%
2025 12.66%
2024 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$548.36 39.87%
US
$1.06K 50.29%
NL
$121.16 -12.75%
AU
$140.81 475.44%
US
$765.25 7.74%
CH